Market Closed -
Bombay S.E.
06:00:50 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
85.45
INR
|
+4.98%
|
|
-1.04%
|
+55.90%
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
698.3
|
351.2
|
152.3
|
234.3
|
730.1
|
584.8
|
Enterprise Value (EV)
1 |
1,296
|
890.9
|
613.3
|
727
|
1,074
|
926.1
|
P/E ratio
|
15.5
x
|
-50.8
x
|
-3.07
x
|
-36.7
x
|
11.4
x
|
8.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.76
x
|
0.43
x
|
0.22
x
|
0.26
x
|
0.61
x
|
0.53
x
|
EV / Revenue
|
1.42
x
|
1.1
x
|
0.88
x
|
0.81
x
|
0.9
x
|
0.84
x
|
EV / EBITDA
|
9.36
x
|
8.22
x
|
-14.4
x
|
8.62
x
|
6.13
x
|
5.97
x
|
EV / FCF
|
-6.68
x
|
14
x
|
16
x
|
-19.7
x
|
9.7
x
|
-43.9
x
|
FCF Yield
|
-15%
|
7.12%
|
6.23%
|
-5.07%
|
10.3%
|
-2.28%
|
Price to Book
|
1.47
x
|
0.75
x
|
0.34
x
|
0.54
x
|
1.46
x
|
1.04
x
|
Nbr of stocks (in thousands)
|
10,255
|
10,255
|
10,255
|
10,255
|
10,255
|
10,255
|
Reference price
2 |
68.10
|
34.25
|
14.85
|
22.85
|
71.20
|
57.03
|
Announcement Date
|
9/3/18
|
9/3/19
|
9/5/20
|
9/6/21
|
8/30/22
|
9/2/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
916.2
|
812
|
700.2
|
902.9
|
1,192
|
1,105
|
EBITDA
1 |
138.6
|
108.4
|
-42.74
|
84.36
|
175.4
|
155.1
|
EBIT
1 |
91.2
|
51.45
|
-102
|
25.18
|
115
|
91.74
|
Operating Margin
|
9.95%
|
6.34%
|
-14.56%
|
2.79%
|
9.65%
|
8.3%
|
Earnings before Tax (EBT)
1 |
63.11
|
-8.764
|
-30
|
-5.532
|
92.65
|
94.83
|
Net income
1 |
44.94
|
-6.916
|
-49.64
|
-6.379
|
64.21
|
66.82
|
Net margin
|
4.9%
|
-0.85%
|
-7.09%
|
-0.71%
|
5.39%
|
6.05%
|
EPS
2 |
4.380
|
-0.6744
|
-4.840
|
-0.6221
|
6.261
|
6.516
|
Free Cash Flow
1 |
-194.2
|
63.46
|
38.24
|
-36.87
|
110.8
|
-21.11
|
FCF margin
|
-21.19%
|
7.82%
|
5.46%
|
-4.08%
|
9.29%
|
-1.91%
|
FCF Conversion (EBITDA)
|
-
|
58.57%
|
-
|
-
|
63.16%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
172.51%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/3/18
|
9/3/19
|
9/5/20
|
9/6/21
|
8/30/22
|
9/2/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
598
|
540
|
461
|
493
|
344
|
341
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.317
x
|
4.981
x
|
-10.79
x
|
5.84
x
|
1.962
x
|
2.2
x
|
Free Cash Flow
1 |
-194
|
63.5
|
38.2
|
-36.9
|
111
|
-21.1
|
ROE (net income / shareholders' equity)
|
9.95%
|
-1.47%
|
-5.18%
|
-1.44%
|
13.7%
|
12.6%
|
ROA (Net income/ Total Assets)
|
4.37%
|
2.3%
|
-4.76%
|
1.25%
|
6.24%
|
4.98%
|
Assets
1 |
1,029
|
-301.1
|
1,043
|
-508.3
|
1,029
|
1,343
|
Book Value Per Share
2 |
46.30
|
45.60
|
43.50
|
42.60
|
48.70
|
54.60
|
Cash Flow per Share
2 |
0.7900
|
1.080
|
1.310
|
0.5400
|
0.2600
|
0.5700
|
Capex
1 |
156
|
55.9
|
8.15
|
68.4
|
90.4
|
42
|
Capex / Sales
|
17.04%
|
6.88%
|
1.16%
|
7.58%
|
7.59%
|
3.8%
|
Announcement Date
|
9/3/18
|
9/3/19
|
9/5/20
|
9/6/21
|
8/30/22
|
9/2/23
|
|
1st Jan change
|
Capi.
|
---|
| +55.90% | 9.99M | | +22.69% | 43.81B | | +25.56% | 23.01B | | +18.70% | 15.27B | | +8.91% | 13.68B | | +42.72% | 11.96B | | -7.49% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.26% | 5.59B |
Generic Pharmaceuticals
|